EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Utah Medical Products Inc (UTMD) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Utah Medical Products Inc $76.05, price $75.01, upside +1.4%, quality 75 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US9174881089

UM Utah Medical Products Inc logo Broad data Sep 23, 2026

Utah Medical Products Inc

UTMD · US

Quality WatchlistA strong company, but the current price is close to Fair Value.

·Fair value $76.05 · Fairly valued (+1%)
✓Quality 75/100
!Weak Growth (revenue 5y −1.8 %/yr)
✓Highly profitable · 28.9% net margin (TTM)
✓Low debt · generates free cash flow
·1.64% dividend yield
✓Ranks above peers (10/15)
✓Wide moat 71/100
Watch Utah Medical Products Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$113.59 $50.46 Fair Value $76.05 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $50.46 – $113.59 · fair‑value band $58.49 – $92.18 · the $75.01 price screens below the $76.05 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Utah Medical Products in your weekly email

Every Wednesday you see whether Utah Medical Products is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.

Show more

Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Stock analysis

Utah Medical Products Inc (UTMD) currently trades at $75.01, while our model-based Fair Value estimate is $76.05, implying the stock looks roughly 1.4% fairly valued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $69.73 per share, and 6 of the 24 models we run sit above the $75.01 price.

Bear case: the Dividend Discount group reads lowest at $9.44, and 18 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: $58.49 (bear) to $92.18 (bull), the price of $75.01 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 75/100 (high quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Utah Medical Products Inc reported revenue of $38.5M in FY2025 versus $49.1M in FY2021, a compound −5.9%/yr. Reported net income was $11.3M in FY2025, compounding −6.5%/yr from FY2021.

Key figures

Market cap $243M · P/E ratio 22.2 · P/S ratio 6.50 · EPS (TTM) $3.38 · Dividend yield 1.6% · Net margin 29.3% · Return on equity 9.1% · Return on assets (EBIT) 13.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (medium confidence).

What moves the price

The share trades about 2% below its 52-week high and 42% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 1%, UTMD screens cheaper than that median.

Fair Value models

Bear $58.49 Fair Value $76.05 Bull $92.18
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($1.57 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $61.38 $69.73 $83.92 82
Growth DCF $62.17 $70.05 $82.38 80
Owner Earnings $60.47 $68.59 $82.41 78
All 24 models by family
DCF Models
FCF DCF $61.38 $69.73 $83.92 82
Owner Earnings $60.47 $68.59 $82.41 78
5Y Revenue Exit $55.54 $65.32 $79.77 74
5Y EBITDA Exit $64.77 $81.10 $103.13 77
5Y P/E Exit $69.75 $89.63 $113.78 72
10Y Revenue Exit $57.62 $64.91 $72.62 68
10Y EBITDA Exit $62.93 $73.49 $84.84 70
10Y P/E Exit $65.54 $78.13 $90.41 65
Earnings-Based
Graham-Dodd $24.10 $34.03 $39.83 67
EPV $46.18 $48.49 $50.36 74
Dividend Discount
Gordon GGM $8.71 $9.44 $10.39 69
DDM Multi-Stage $8.71 $10.36 $12.22 67
Multiples
P/E Multiple $58.49 $77.98 $97.48 63
P/S Multiple $31.76 $42.34 $52.93 58
P/B Multiple $45.19 $60.26 $75.32 55
EV/EBIT $72.59 $87.81 $103.03 66
EV/EBITDA $74.45 $90.29 $106.13 67
EV/Revenue $52.34 $63.23 $74.11 54
Asset-Based
NCAV (Graham) $18.73 $25.10 $37.46 54
Growth DCF
Growth DCF $62.17 $70.05 $82.38 80
Rev-Margin DCF $55.54 $66.27 $79.98 74
Economic Profit
Residual Income $29.20 $30.88 $33.08 76
ROIC Compounder $46.27 $49.02 $51.65 72
Growth Earnings
Growth-Adj P/E $41.23 $58.90 $76.57 67

Open the full fair value analysis →

Notify me when UTMD reaches fair value

Put UTMD on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 75/100

Of which business quality 72 · Market factors (momentum, volatility) 71

Profitability 49
Margins and returns on capital today
Quality Growth 17
Are margins and returns improving?
Cashflow 88
Earnings quality: real cash, not paper profit
Fin. Strength 83
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 86
Calm price path (market factor)
Momentum 59
Price trend over the last 3–12 months (market factor)
52W Momentum 75
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
Start year 2020 (pandemic). Over 10 years: −0.4% a year
Revenue growth 38 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−0.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.4%
Dividend (yield on the price)1.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2% vs 1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.33% → 30%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about 0.0% a year for the price.

Watch UTMD, get fair value alerts →

Compare Utah Medical Products Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 75 · Top 25%
Fair Value upside +1% · Above median
Profitability
Return on equity (TTM) 9% · Above median
Return on assets 6% · Above median
Net margin (TTM) 29% · Top 25%
Operating margin (TTM) 34% · Top 25%
Growth and dividend
Revenue growth −10% · Bottom 25%
Dividend yield (TTM) 1.6% · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 22.2× · Cheaper than median
P/B 2.04× · Pricier than median
P/S (TTM) 6.48× · Priciest 25%
P/FCF 17.0× · Pricier than median
EV/EBITDA 10.3× · Cheaper than median
PEG 4.25× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)35 · sector 18
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)37 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)33 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.09 $353.38 −12%
EssilorLuxottica Société anonyme EL €144.70 €159.17 +10%
Medline Inc MDLN $34.30 $30.15 −12%
Becton, Dickinson and Company BDX $182.52 $103.53 −43%
Alcon Inc ALC $65.39 $39.78 −39%
ResMed Inc RMD A$31.70 A$34.87 +10%
West Pharmaceutical Services, Inc WST $375.87 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €215.80 €54.82 −75%
Straumann Holding STMN CHF 96.38 CHF 45.50 −53%
Solventum Corporation SOLV $88.75 $130.51 +47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Utah Medical Products Inc · Fair Value
$76.05 +1%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Utah Medical Products Inc Fair Value". https://www.fairvalue-calculator.com/stock/UTMD

Frequently asked questions

Is Utah Medical Products Inc (UTMD) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $76.05 versus a price of $75.01, about +1% upside (fairly valued).
What is the fair value of UTMD?
Our model-based fair value for Utah Medical Products Inc is $76.05 (as of Sep 23, 2026), built from audited fundamentals. The current price: $75.01.
What is the quality score of UTMD?
Utah Medical Products Inc has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Utah Medical Products Inc (UTMD)?
Our model-based price target is the fair value of $76.05 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $58.49, optimistic scenario $92.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Utah Medical Products Inc stock forecast for 2026?
Our models put fair value at $76.05, about +1% upside versus a price of $75.01 (fairly valued). Cautious scenario $58.49, optimistic scenario $92.18. The calculation is refreshed regularly with new filings.
What is the revenue of Utah Medical Products Inc (UTMD)?
Utah Medical Products Inc reported trailing-twelve-month revenue of about $37.5M (latest available figure, as of Sep 23, 2026).
Does Utah Medical Products Inc pay a dividend?
Utah Medical Products Inc currently shows a dividend yield of about 1.64% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Utah Medical Products Inc (UTMD)?
For today's price to be fair in a discounted-cash-flow model, Utah Medical Products Inc would have to grow free cash flow by +2.3 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.8 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of UTMD use?
Our models discount Utah Medical Products Inc at 11.2 %: a base by market capitalisation (micro), damped by beta 0.37, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Utah Medical Products Inc that is +2.3 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Utah Medical Products Inc (UTMD) delivered so far?
Over the past 5 years revenue at Utah Medical Products Inc grew -1.8 % a year. The price currently implies +2.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Utah Medical Products Inc (UTMD) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Utah Medical Products Inc (+2.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Utah Medical Products Inc (UTMD)?
The free-cash-flow yield on the price is 5.89 %: that much free cash flow Utah Medical Products Inc produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Utah Medical Products Inc (UTMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Utah Medical Products Inc it is $76.05 per share (as of Sep 23, 2026), against a price of $75.01. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Utah Medical Products Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, UTMD trades below its calculated fair value: price $75.01, fair value $76.05, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of UTMD?
No. The price is what the market pays today ($75.01); the fair value is what the company's own numbers justify ($76.05). For Utah Medical Products Inc the two are $1.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is Utah Medical Products Inc worth?
The market values Utah Medical Products Inc at about $243M (market capitalisation, as of Sep 23, 2026). Per share that is $75.01; our models calculate a fair value of $76.05 per share.
What do the bullish and bearish scenarios say about UTMD?
Our models span a range for Utah Medical Products Inc: cautious scenario $58.49, base $76.05, optimistic $92.18 per share (as of Sep 23, 2026, price $75.01). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of UTMD?
Utah Medical Products Inc trades at a price-to-earnings ratio of 22.2 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $76.05 is built from several models across several years. Other multiples: PEG 4.3, P/B 2.0, P/S 6.5, EV/EBITDA 10.3.
What is the PEG ratio of UTMD?
The PEG ratio of Utah Medical Products Inc is 4.25 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Utah Medical Products Inc (UTMD)?
Balance-sheet figures for Utah Medical Products Inc (as of Sep 23, 2026): return on equity 9.1%. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is UTMD from its 52-week high?
Utah Medical Products Inc trades at $75.01, about 2% below its 52-week high of $76.66 and 42% above the low of $53.01 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $76.05 is for.
Which stocks are comparable to Utah Medical Products Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Utah Medical Products Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $75.01, calculated fair value $76.05 (+1%), Quality Score 75/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of UTMD calculated?
We run Utah Medical Products Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $76.05, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Utah Medical Products Inc currently trades 1 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Utah Medical Products Inc (UTMD)?
The closing price on Sep 23, 2026 was $75.01. Our model-based fair value is $76.05, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Utah Medical Products Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Utah Medical Products Inc (UTMD) come from?
Earnings per share at Utah Medical Products Inc grew +2.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +1.8 %, EBIT margin −2.3 %, tax rate +1.1 %, residual (interest, one-offs) +2.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Utah Medical Products Inc

How large is the market capitalisation of Utah Medical Products Inc (UTMD)?
The market capitalisation of Utah Medical Products Inc is $243M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Utah Medical Products Inc (UTMD)?
The price-to-sales ratio of Utah Medical Products Inc is 6.50 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Utah Medical Products Inc (UTMD)?
Earnings per share at Utah Medical Products Inc are $3.38 (price ÷ EPS = P/E 22.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Utah Medical Products Inc (UTMD)?
The dividend yield of Utah Medical Products Inc is 1.6% (payout 36.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Utah Medical Products Inc (UTMD)?
The net margin of Utah Medical Products Inc is 29.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Utah Medical Products Inc (UTMD)?
The return on equity (ROE) of Utah Medical Products Inc is 9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Utah Medical Products Inc (UTMD)?
On an EBIT basis the return on assets of Utah Medical Products Inc is 13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Utah Medical Products Inc (UTMD)?
The operating margin of Utah Medical Products Inc is 34.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Utah Medical Products Inc (UTMD)?
Revenue at Utah Medical Products Inc is growing −10.2% versus a year earlier (3y avg −9.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Utah Medical Products Inc (UTMD)?
Earnings per share at Utah Medical Products Inc are growing −11.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Utah Medical Products Inc (UTMD) hold?
Utah Medical Products Inc holds more cash than debt, $85.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Utah Medical Products Inc in the live analysis

One click puts Utah Medical Products Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.